Elucid Names Kelly Huang as CEO

August 1, 2024—Elucid recently announced it has named Kelly Huang, PhD, as president and chief executive officer (CEO).

Dr. Huang previously served as chief operating officer (COO) for Cardea Bio, a producer of biocompatible semiconductors, which was acquired by Paragraf in 2023. Before that, he was COO for and head of Nutra-Therapeutic at L-Nutra, Inc. and president and CEO at Obalon Therapeutics; and held senior leadership roles at Nestle/Galderma, Endo Pharmaceuticals, and Johnson & Johnson.

Dr. Huang holds a PhD in chemical engineering from Stanford University in Stanford, California.

The company noted that the appointment of Dr. Huang comes as Elucid prepares for commercialization of PlaqueIQ, its flagship FDA-cleared plaque analysis software. Elucid’s CT angiography algorithm objectively quantifies and characterizes plaque validated against ground truth histology.

On July 18, Elucid announced the initiation of site recruitment for the international, multicenter, retrospective PRE-VUE CT Registry study, which is evaluating the prognostic accuracy of PlaqueIQ as well as its investigational plaque-based FFR_CT software in predicting major cardiac adverse events in patients who have received clinically indicated coronary CT angiography.